IP Library Granted Patent US 8,524,494
Granted Patent B2
US 8,524,494 · App. 12/547,422 · Granted Sep 3, 2013

Low oxygen tension and BFGF generates a multipotent stem cell from a fibroblast in vitro

Inventors: Gail K. Naughton (San Diego, CA); Frank Ziegler (Encinitas, CA); Mark Baumgartner (San Diego, CA); Kyle Nickey (Vista, CA)
Assignee: Histogen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,494
App. No.
12/547,422
Granted
Sep 3, 2013
Kind
B2
Abstract

The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.

Claims (7)

1. A method of generating a multipotent stem cell comprising culturing fibroblast cells under conditions to induce de-differentiation of the fibroblast cells, wherein the conditions are from about 1-5% oxygen on a microcarrier bead surface in a suitable growth medium containing basic FGF (bFGF), thereby generating cells that express genes characteristic of multipotent stem cells.

2. The method of claim 1 , where the genes are selected from the group consisting of Oct4, Sox2, KLF4, NANOG and cMyc.

3. The method of claim 2 , wherein the gene is Oct4.

4. The method of claim 1 , wherein the expressed genes are characteristic of embryonic stem cells, mesenchymal stem cells or neuronal stem cells.

5. The method of claim 1 , wherein the growth medium comprises serum.

6. The method of claim 1 , wherein the growth medium is serum-free.

7. The method of claim 1 , wherein the fibroblasts are neonatal fibroblasts.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2024
From: HISTOGEN INC.
To: ALLERGAN SALES, LLC
Reel/Frame 067559/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2012
From: NAUGHTON, GAIL K.; ZIEGLER, FRANK; BAUMGARTNER, MARK; NICKEY, KYLE
To: HISTOGEN, INC.
Reel/Frame 028368/0869 →
Continuity (7)
Continuation In Part 12509171 · Jul 24, 2009
Continuation In Part 12501312 · Jul 10, 2009
Continuation In Part 12563488 · Jan 30, 2009
Provisional Application 61024854 · Jan 30, 2008
Provisional Application 61034361 · Mar 6, 2008
Provisional Application 61050940 · May 6, 2008
Related Publication 20100196963A1 · Aug 5, 2010